Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
Associated Disease
Her2-receptor positive breast cancer
Source Database
CIViC Evidence
Description
With multiple mechanisms of HER reprogramming thought to be behind trastuzumab resistance, including increased expression of ErbB members, afatinib, which broadly and irreversibly targets ErbB receptors was tested in a single arm phase II trial on advanced stage HER2 positive metastatic breast cancer. From 41 treated patients, 10% had partial response, 37% had stable disease as best response and 46% achieved clinical benefit. Median progression free survival (PFS) was 15.1 weeks and median overall survival (OS) was 61.0 weeks. The authors conclude that Afatinib monotherapy shows promise in treatment of metastatic HER2 positive breast cancer that has progressed under trastuzumab.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1010
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/306
Rating
3
Evidence Type
Predictive
Disease
Her2-receptor Positive Breast Cancer
Evidence Direction
Supports
Drug
Afatinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
22418700
Drugs
Drug NameSensitivitySupported
AfatinibSensitivitytrue